ARS Pharmaceuticals (SPRY) EBITDA (2020 - 2026)

ARS Pharmaceuticals has disclosed EBITDA across 7 years of filings, most recently posting -$60.8 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$60.8 million, down 78.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$198.1 million (down 1182.15% YoY), and the FY2025 annual result was -$171.4 million, down 2198.09% from the prior year.
• EBITDA came in at -$60.8 million for Q1 2026 at ARS Pharmaceuticals, down from -$41.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $49.8 million in Q4 2024 to a low of -$60.8 million in Q1 2026.
• The 5-year median for EBITDA is -$14.8 million (2023), against an average of -$18.4 million.
• Across the five-year window, EBITDA soared 815.94% in 2024 and sank 258.95% in 2025, its largest moves.
• ARS Pharmaceuticals' EBITDA stood at -$14.0 million in 2022, then soared by 50.38% to -$7.0 million in 2023, then jumped by 815.94% to $49.8 million in 2024, then tumbled by 182.69% to -$41.2 million in 2025, then slumped by 47.7% to -$60.8 million in 2026.
• The last three EBITDA figures came in at -$60.8 million (Q1 2026), -$41.2 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.